Mechanism of drug resistance in mycobacterium tuberculosis

Bacterial Resistance to Antimicrobials, Second Edition

Volumn , Issue , 2007, Pages 313-342

  Pym, Alex S ^a   Cole, Stewart T ^b  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873118897     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (195)

1. Dye, C. 2006. Global epidemiology of tuberculosis. Lancet 367:938-40.
2. Zignol, M., M. S. Hosseini, A. Wright, C. L. Weezenbeek, P. Nunn, C. J. Watt, B. G. Williams, and C. Dye. 2006. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194:479-85.
3. Schatz, A., E. Bugie, and S. A. Waksman. 1944. Streptomycin. Substance exhibiting activity against Gram-positive and Gram-negative bacteria. Proc Soc Exp Biol Med 55:66-9.
4. Lehman, J. 1946. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 250:15-6.
5. Pfuetze, K. H., M. M. Pyle, and H. C. Hinshaw. 1955. The first clinical trial of streptomycin in human tuberculosis. Am Rev Tuberc 71:752-4.
6. Council, M. R. 1948. Medical Research Council streptomycin treatment of pulmonary tuberculosis. Br Med J 2:769-82.
7. Fox, W., I. Sutherland, and M. Daniels. 1954. A five year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis. Quart J Med 23:347-366.
8. Council, M. R. 1950. Medical Research Council treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. Br Med J 2:1073-85.
9. Robitzek, E. H., and I. J. Selikoff. 1952. Hydrazine derivatives of isonicotinic acid (Rimifon, Marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis. A preliminary report. Am Rev Tuberc 65:402-28.
10. Council, M. R. 1955. Various combinations of isoniazid with streptomycin or with PAS in the treatment of pulmonary tuberculosis. Br Med J 1:435-45.
11. Canetti, G. 1959. Modifications des populations des foyers tuberculeux au cours de la chimiothérapie antibacillaire. Ann Inst Pasteur 97:53-79.
12. Canetti, G., and J. Grosset. 1961. Teneur des souches sauvages de Mycobacterium tuberculosis en variants résistants à la streptomycine sur milieu de Lowenstein-Jensen. Ann Inst Pasteur 101:28-46.
13. David, H. L. 1970. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 20:810-4.
14. Fox, W., G. A. Ellard, and D. A. Mitchison. 1999. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3:S231-79.
15. Yeager, R., W. E. Monroe, and F. I. Dessau. 1952. Pyrazinamide in the treatment of pulmonary tuberculosis. Am Rev Tuberc 65:523-546.
16. Sensi, P., A. M. Greco, and R. Ballotta. 1960. Rifomycin. I. Isolation and properties of rifomycin B and rifomycin complex. Antibiotics Annual 1959:262-270.
17. Mitchison, D. A., and A. J. Nunn. 1986. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133:423-30.
18. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to secondline drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 55:301-5.
19. Gandhi, N. R., A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-80.
20. Kopanoff, D. E., J. O. Kilburn, J. L. Glassroth, D. J. Snider, L. S. Farer, and R. C. Good. 1978. A continuing survey of tuberculosis primary drug resistance in the United States:March 1975 to November 1977. A United States Public Health Service cooperative study. Am Rev Respir Dis 118:835-42.
21. Beck, S. C., S. W. Dooley, M. D. Hutton, J. Otten, A. Breeden, J. T. Crawford, A. E. Pitchenik, C. Woodley, G. Cauthen, and W. R. Jarvis. 1992. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 268:1280-6.
22. Edlin, B. R., J. I. Tokars, M. H. Grieco, J. T. Crawford, J. Williams, E. M. Sordillo, K. R. Ong, J. O. Kilburn, S. W. Dooley, K. G. Castro, et al. 1992. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 326:1514-21.
23. Small, P. M., R. W. Shafer, P. C. Hopewell, S. P. Singh, M. J. Murphy, E. Desmond, M. F. Sierra, and G. K. Schoolnik. 1993. Exogenous reinfection with multidrugresistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 328:1137-44.
24. Valway, S. E., S. B. Richards, J. Kovacovich, R. B. Greifinger, J. T. Crawford, and S. W. Dooley. 1994. Outbreak of multi-drug-resistant tuberculosis in a New York State prison, 1991. Am J Epidemiol 140:113-22.
25. Morb Mortal Wkly Rep. 1996. Multidrug-resistant tuberculosis outbreak on an HIV ward-Madrid, Spain, 1991-1995. Morb Mortal Wkly Rep 45:330-3.
26. Portugal, I., M. J. Covas, L. Brum, M. Viveiros, P. Ferrinho, P. J. Moniz, and H. David. 1999. Outbreak of multiple drug-resistant tuberculosis in Lisbon: detection by restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 3:207-13.
27. Ritacco, V., L. M. Di, A. Reniero, M. Ambroggi, L. Barrera, A. Dambrosi, B. Lopez, N. Isola, and K. I. de. 1997. Nosocomial spread of human immunodeficiency virusrelated multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis 176:637-42.
28. Frieden, T. R., T. Sterling, M. A. Pablos, J. O. Kilburn, G. M. Cauthen, and S. W. Dooley. 1993. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328:521-6.
29. Moss, A. R., D. Alland, E. Telzak, D. J. Hewlett, V. Sharp, P. Chiliade, V. LaBombardi, D. Kabus, B. Hanna, L. Palumbo, K. Brudney, A. Weltman, K. Stoeckle, K. Chirgwin, M. Simberkoff, S. Moghazeh, W. Eisner, M. Lutfey, and B. Kreiswirth. 1997. A citywide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis 1:115-21.
30. Agerton, T. B., S. E. Valway, R. J. Blinkhorn, K. L. Shilkret, R. Reves, W. W. Schluter, B. Gore, C. J. Pozsik, B. B. Plikaytis, C. Woodley, and I. M. Onorato. 1999. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. Clin Infect Dis 29:85-92.
31. WHO. 2004. Anti-tuberculosis Drug Resistance in the World-Third Global Report. World Health Organization: Geneva, Switzerland WHO/HTM/TB/2004.343.
32. Noller, H. F. 1984. Structure of ribosomal RNA. Annu Rev Biochem 53:119-62.
33. Ainsa, J. A., E. Perez, V. Pelicic, F. X. Berthet, B. Gicquel, and C. Martin. 1997. Aminoglycoside 2'-N-acetyltransferase genes are universally present in mycobacteria: characterization of the aac(2 ')-Ic gene from Mycobacterium tuberculosis and the aac(2')-Id gene from Mycobacterium smegmatis. Mol Microbiol 24:431-41.
34. Ramon-Garcia, S., I. Otal, C. Martin, R. Gomez-Lus, and J. A. Ainsa. 2006. Novel streptomycin resistance gene from Mycobacterium fortuitum. Antimicrob Agents Chemother 50:3920-2.
35. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry III, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, A. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M.-A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. Barrell. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-44.
36. Cooksey, R. C., G. P. Morlock, A. McQueen, S. E. Glickman, and J. T. Crawford. 1996. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City. Antimicrob Agents Chemother 40:1186-8.
37. Finken, M., P. Kirschner, A. Meier, A. Wrede, and E. C. Bottger. 1993. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis : alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 9:1239-46.
38. Honore, N., and S. T. Cole. 1994. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 38:238-42.
39. Nair, J., D. A. Rouse, G. H. Bai, and S. L. Morris. 1993. The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. Mol Microbiol 10:521-7.
40. Sreevatsan, S., X. Pan, K. E. Stockbauer, D. L. Williams, B. N. Kreiswirth, and J. M. Musser. 1996. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob Agents Chemother 40:1024-6.
41. Moazed, D., and H. F. Noller. 1987. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 327:389-94.
42. Leclerc, D., P. Melancon, and G. L. Brakier. 1991. Mutations in the 915 region of Escherichia coli 16S ribosomal RNA reduce the binding of streptomycin to the ribosome. Nucleic Acids Res 19:3973-7.
43. Powers, T., and H. F. Noller. 1991. A functional pseudoknot in 16S ribosomal RNA. EMBO J 10:2203-14.
44. De Rossi, E., J. A. Ainsa, and G. Riccardi. 2006. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 30:36-52.
45. Ainsa, J. A., M. C. J. Blokpoel, I. otal, D. B. Young, K. A. L. de Smet, and C. Martin. 1998. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol 180:5836-43.
46. Ramon-Garcia, S., C. Martin, E. De Rossi, and J. A. Ainsa. 2007. Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG. J Antimicrob Chemother 59:544-7.
47. Silva, P. E., F. Bigi, M. P. Santangelo, M. I. Romano, C. Martin, A. Cataldi, and J. A. Ainsa. 2001. Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis. Antimicrob Agents Chemother 45:800-4.
48. Okamoto, S., A. Tamaru, C. Nakajima, K. Nishimura, Y. Tanaka, S. Tokuyama, Y. Suzuki, and K. Ochi. 2007. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol Microbiol 63:1096-106.
49. Meier, A., P. Sander, K. J. Schaper, M. Scholz, and E. C. Bottger. 1996. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycinresistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 40:2452-4.
50. Fourmy, D., M. I. Recht, S. C. Blanchard, and J. D. Puglisi. 1996. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274:1367-71.
51. Beauclerk, A. A., and E. Cundliffe. 1987. Sites of action of two ribosomal RNA methylases responsible for resistance to aminoglycosides. J Mol Biol 193:661-71.
52. Alangaden, G. J., B. N. Kreiswirth, A. Aouad, M. Khetarpal, F. R. Igno, S. L. Moghazeh, E. K. Manavathu, and S. A. Lerner. 1998. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:1295-7.
53. Suzuki, Y., C. Katsukawa, A. Tamaru, C. Abe, M. Makino, Y. Mizuguchi, and H. Taniguchi. 1998. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 36:1220-5.
54. Taniguchi, H., B. Chang, C. Abe, Y. Nikaido, Y. Mizuguchi, and S. I. Yoshida. 1997. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system. J Bacteriol 179:4795-801.
55. Prammananan, T., P. Sander, B. A. Brown, K. Frischkorn, G. O. Onyi, Y. Zhang, E. C. Bottger, and R. J. Wallace, Jr. 1998. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis 177:1573-81.
56. Sander, P., T. Prammananan, and E. C. Bottger. 1996. Introducing mutations into a chromosomal rRNA gene using a genetically modified eubacterial host with a single rRNA operon. Mol Microbiol 22:841-8.
57. Kruuner, A., P. Jureen, K. Levina, S. Ghebremichael, and S. Hoffner. 2003. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47:2971-3.
58. Herr, E. B., Jr., and M. O. Redstone. 1966. Chemical and physical characterization of capreomycin. Ann NY Acad Sci 135:940-6.
59. Maus, C. E., B. B. Plikaytis, and T. M. Shinnick. 2005. Molecular analysis of crossresistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:3192-7.
60. Maus, C. E., B. B. Plikaytis, and T. M. Shinnick. 2005. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:571-7.
61. Johansen, S. K., C. E. Maus, B. B. Plikaytis, and S. Douthwaite. 2006. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O -methylations in 16S and 23S rRNAs. Mol Cell 23:173-82.
62. Maggi, N., C. R. Pasqualucci, R. Ballota, and P. Sensi. 1966. Rifampicin: a new orally active rifamycin. Chemotherapia 11:285-92.
63. East Africa, B. M. R. C. 1972. Controlled clinical trial of short course (6 months) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1:1072-85.
64. Hartmann, G., K. O. Honikel, F. Knusel, and J. Nuesch. 1967. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta 145:843-4.
65. Ovchinnikov, Y. A., G. S. Monastyrskaya, S. O. Guriev, N. F. Kalinina, E. D. Sverdlov, A. I. Gragerov, I. A. Bass, I. F. Kiver, E. P. Moiseyeva, V. N. Igumnov, S. Z. Mindlin, V. G. Nikiforov, and R. B. Khesin. 1983. RNA polymerase rifampicin resistance mutations in Escherichia coli : sequence changes and dominance. Mol Gen Genet 190:344-8.
66. Honore, N., S. Bergh, S. Chanteau, P. F. Doucet, K. Eiglmeier, T. Garnier, C. Georges, P. Launois, T. Limpaiboon, S. Newton, and a. l. et. 1993. Nucleotide sequence of the first cosmid from the Mycobacterium leprae genome project: structure and function of the Rif-Str regions. Mol Microbiol 7:207-14.
67. Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. Colston, L. Matter, K. Schopfer, and T. Bodmer. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-50.
68. Honore, N., and S. T. Cole. 1993. Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother 37:414-8.
69. Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis : 1998 update. Tuber Lung Dis 79:3-29.
70. Miller, L. P., J. T. Crawford, and T. M. Shinnick. 1994. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother 38:805-11.
71. Williams, D. L., L. Spring, L. Collins, L. P. Miller, L. B. Heifets, P. R. Gangadharam, and T. P. Gillis. 1998. Contribution of rpoB mutations to development of rifamycin crossresistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:1853-7.
72. Musser, J. M. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 8:496-514.
73. Guerrero, C., L. Stockman, F. Marchesi, T. Bodmer, G. D. Roberts, and A. Telenti. 1994. Evaluation of the rpoB gene in rifampicin-susceptible and -resistant Mycobacterium avium and Mycobacterium intracellulare. J Antimicrob Chemother 33:661-3.
74. Quan, S., H. Venter, and E. R. Dabbs. 1997. Ribosylative inactivation of rifampin by Mycobacterium smegmati s is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemother 41:2456-60.
75. Middlebrook, G. 1954. Isoniazid-resistance and catalase activities of tubercle bacilli. A preliminary report. Am Rev Tuberc 69:471-2.
76. Middlebrook, G., and M. L. Cohn. 1953. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 118:297-9.
77. Winder, F. G. 1982. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of mycobacteria. In: Ratledge C, Stanford J, eds. The Biology of Mycobacteria. New York, Academic Press:353-438.
78. Kruger-Thiemer, E. 1958. Isonicotinic acid hypothesis of the antituberculous action of isoniazid. Am Rev Tuberc 77:364-7.
79. Zhang, Y., B. Heym, B. Allen, D. Young, and S. Cole. 1992. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-3.
80. Zhang, Y., T. Garbe, and D. Young. 1993. Transformation with katG restores isoniazidsensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol 8:521-4.
81. Heym, B., P. M. Alzari, N. Honore, and S. T. Cole. 1995. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 15:235-45.
82. Johnsson, K., W. A. Froland, and P. G. Schultz. 1997. Overexpression, purification, and characterization of the catalase-peroxidase KatG from Mycobacterium tuberculosis. J Biol Chem 272:2834-40.
83. Johnsson, K., and P. G. Schultz. 1994. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 116:7425-26.
84. Bertrand, T., N. A. Eady, J. N. Jones, Jesmin, J. M. Nagy, B. Jamart-Gregoire, E. L. Raven, and K. A. Brown. 2004. Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. J Biol Chem 279:38991-9.
85. Pierattelli, R., L. Banci, N. A. Eady, J. Bodiguel, J. N. Jones, P. C. Moody, E. L. Raven, B. Jamart-Gregoire, and K. A. Brown. 2004. Enzyme-catalyzed mechanism of isoniazid activation in class I and class III peroxidases. J Biol Chem 279:39000-9.
86. Gagneux, S., M. V. Burgos, K. DeRiemer, A. Encisco, S. Munoz, P. C. Hopewell, P. M. Small, and A. S. Pym. 2006. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2:e61.
87. Hazbon, M. H., M. Brimacombe, M. Bobadilla del Valle, M. Cavatore, M. I. Guerrero, M. Varma-Basil, H. Billman-Jacobe, C. Lavender, J. Fyfe, L. Garcia-Garcia, C. I. Leon, M. Bose, F. Chaves, M. Murray, K. D. Eisenach, J. Sifuentes-Osornio, M. D. Cave, A. Ponce de Leon, and D. Alland. 2006. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 50:2640-9.
88. Ramaswamy, S. V., R. Reich, S. J. Dou, L. Jasperse, X. Pan, A. Wanger, T. Quitugua, and E. A. Graviss. 2003. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 47:1241-50.
89. Saint-Joanis, B., H. Souchon, M. Wilming, K. Johnsson, P. M. Alzari, and S. T. Cole. 1999. Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis. Biochem J 338:753-60.
90. Wengenack, N. L., S. Todorovic, L. Yu, and F. Rusnak. 1998. Evidence for differential binding of isoniazid by Mycobacterium tuberculosis KatG and the isoniazid-resistant mutant KatG(S315T). Biochemistry 37:15825-34.
91. Wengenack, N. L., J. R. Uhl, A. A. St, A. J. Tomlinson, L. M. Benson, S. Naylor, B. C. Kline, F. r. Cockerill, and F. Rusnak. 1997. Recombinant Mycobacterium tuberculosis KatG(S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid. J Infect Dis 176:722-7.
92. Ng, V. H., J. S. Cox, A. O. Sousa, J. D. MacMicking, and J. D. McKinney. 2004. Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst. Mol Microbiol 52:1291-302.
93. Heym, B., E. Stavropoulos, N. Honore, P. Domenech, J. B. Saint, T. M. Wilson, D. M. Collins, M. J. Colston, and S. T. Cole. 1997. Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infect Immun 65:1395-401.
94. Jackett, P. S., V. R. Aber, and D. B. Lowrie. 1978. Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis. J Gen Microbiol 104:37-45.
95. Manca, C., S. Paul, C. R. Barry, V. H. Freedman, and G. Kaplan. 1999. Mycobacterium tuberculosis catalase and peroxidase activities and resistance to oxidative killing in human monocytes in vitro. Infect Immun 67:74-9.
96. Pym, A. S., B. Saint-Joanis, and S. T. Cole. 2002. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 70:4955-60.
97. Carpena, X., S. Loprasert, S. Mongkolsuk, J. Switala, P. C. Loewen, and I. Fita. 2003. Catalase-peroxidase KatG of Burkholderia pseudomallei at 1.7A resolution. J Mol Biol 327:475-89.
98. Yamada, Y., T. Fujiwara, T. Sato, N. Igarashi, and N. Tanaka. 2002. The 2.0 A crystal structure of catalase-peroxidase from Haloarcula marismortui. Nat Struct Biol 9:691-5.
99. Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, K. S. Um, T. Wilson, D. Collins, L. G. de, and W. J. Jacobs. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-30.
100. Banerjee, A., M. Sugantino, J. C. Sacchettini, and W. J. Jacobs. 1998. The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance. Microbiology 144:2697-704.
101. Vilcheze, C., F. Wang, M. Arai, M. H. Hazbon, R. Colangeli, L. Kremer, T. R. Weisbrod, D. Alland, J. C. Sacchettini, and W. R. Jacobs, Jr. 2006. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 12:1027-9.
102. Quemard, A., J. C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W. J. Jacobs, and J. S. Blanchard. 1995. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34:8235-41.
103. Dessen, A., A. Quemard, J. S. Blanchard, W. R. Jacobs, Jr., and J. C. Sacchettini. 1995. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267:1638-41.
104. Rozwarski, D. A., G. A. Grant, D. Barton, W. J. Jacobs, and J. C. Sacchettini. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102.
105. Rawat, R., A. Whitty, and P. J. Tonge. 2003. The isoniazid-NAD adduct is a slow, tightbinding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc Natl Acad Sci USA 100:13881-6.
106. Wilming, M., and K. Johnsson. 1999. Spontaneous formation of the bioactive form of the tuberculosis drug isoniazid. Angew Chem Int Ed Engl 38:2588-90.
107. Miesel, L., T. R. Weisbrod, J. A. Marcinkeviciene, R. Bittman, and W. J. Jacobs. 1998. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J Bacteriol 180:2459-67.
108. Vilcheze, C., T. R. Weisbrod, B. Chen, L. Kremer, M. H. Hazbon, F. Wang, D. Alland, J. C. Sacchettini, and W. R. Jacobs, Jr. 2005. Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 49:708-20.
109. Kuo, M. R., H. R. Morbidoni, D. Alland, S. F. Sneddon, B. B. Gourlie, M. M. Staveski, M. Leonard, J. S. Gregory, A. D. Janjigian, C. Yee, J. M. Musser, B. Kreiswirth, H. Iwamoto, R. Perozzo, W. R. Jacobs, Jr., J. C. Sacchettini, and D. A. Fidock. 2003. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J Biol Chem 278:20851-9.
110. Parikh, S. L., G. Xiao, and P. J. Tonge. 2000. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39:7645-50.
111. Sullivan, T. J., J. J. Truglio, M. E. Boyne, P. Novichenok, X. Zhang, C. F. Stratton, H. J. Li, T. Kaur, A. Amin, F. Johnson, R. A. Slayden, C. Kisker, and P. J. Tonge. 2006. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem Biol 1:43-53.
112. Mdluli, K., D. R. Sherman, M. J. Hickey, B. N. Kreiswirth, S. Morris, C. K. Stover, and C. E. Barry. 1996. Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J Infect Dis 174:1085-90.
113. Mdluli, K., R. A. Slayden, Y. Zhu, S. Ramaswamy, X. Pan, D. Mead, D. D. Crane, J. M. Musser, and C. r. Barry. 1998. Inhibition of a Mycobacterium tuberculosis betaketoacyl ACP synthase by isoniazid. Science 280:1607-10.
114. Lee, A. S., I. H. Lim, L. L. Tang, A. Telenti, and S. Y. Wong. 1999. Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother 43:2087-9.
115. Piatek, A. S., A. Telenti, M. R. Murray, H. H. El, W. J. Jacobs, F. R. Kramer, and D. Alland. 2000. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 44:103-10.
116. Kremer, L., L. G. Dover, H. R. Morbidoni, C. Vilcheze, W. N. Maughan, A. Baulard, S. C. Tu, N. Honore, V. Deretic, J. C. Sacchettini, C. Locht, W. R. Jacobs, Jr., and G. S. Besra. 2003. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J Biol Chem 278:20547-54.
117. Larsen, M. H., C. Vilcheze, L. Kremer, G. S. Besra, L. Parsons, M. Salfinger, L. Heifets, M. H. Hazbon, D. Alland, J. C. Sacchettini, and W. R. Jacobs, Jr. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 46:453-66.
118. Argyrou, A., M. W. Vetting, B. Aladegbami, and J. S. Blanchard. 2006. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat Struct Mol Biol 13:408-13.
119. Alland, D., A. J. Steyn, T. Weisbrod, K. Aldrich, and W. J. Jacobs. 2000. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J Bacteriol 182:1802-11.
120. Colangeli, R., D. Helb, S. Sridharan, J. Sun, M. Varma-Basil, M. H. Hazbon, R. Harbacheuski, N. J. Megjugorac, W. R. Jacobs, Jr., A. Holzenburg, J. C. Sacchettini, and D. Alland. 2005. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol 55:1829-40.
121. Pasca, M. R., P. Guglierame, E. De Rossi, F. Zara, and G. Riccardi. 2005. mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. Antimicrob Agents Chemother 49:4775-7.
122. Andersson, D. I., and B. R. Levin. 1999. The biological cost of antibiotic resistance. Curr Opin Microbiol 2:489-93.
123. Bjorkman, J., D. Hughes, and D. I. Andersson. 1998. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA 95:3949-53.
124. Maisnier-Patin, S., O. G. Berg, L. Liljas, and D. I. Andersson. 2002. Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol Microbiol 46:355-66.
125. Schrag, S. J., and V. Perrot. 1996. Reducing antibiotic resistance. Nature 381:120-1.
126. Rosner, J. L. 1993. Susceptibilities of oxyR regulon mutants of Escherichia coli and Salmonella typhimurium to isoniazid. Antimicrob Agents Chemother 37:2251-3.
127. Deretic, V., W. Philipp, S. Dhandayuthapani, M. H. Mudd, R. Curcic, T. Garbe, B. Heym, L. E. Via, and S. T. Cole. 1995. Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: implications for sensitivity to isoniazid. Mol Microbiol 17:889-900.
128. Sherman, D. R., K. Mdluli, M. J. Hickey, T. M. Arain, S. L. Morris, C. r. Barry, and C. K. Stover. 1996. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272:1641-3.
129. Sherman, D. R., P. J. Sabo, M. J. Hickey, T. M. Arain, G. G. Mahairas, Y. Yuan, C. r. Barry, and C. K. Stover. 1995. Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria. Proc Natl Acad Sci USA 92:6625-9.
130. Wilson, T., G. W. de Lisle, J. A. Marcinkeviciene, J. S. Blanchard, and D. M. Collins. 1998. Antisense RNA to ahpC, an oxidative stress defence gene involved in isoniazid resistance, indicates that AhpC of Mycobacterium bovis has virulence properties. Microbiology 144:2687-95.
131. Wilson, T. M., L. G. de, and D. M. Collins. 1995. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 15:1009-15.
132. Gagneux, S., C. D. Long, P. M. Small, T. Van, G. K. Schoolnik, and B. J. Bohannan. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-6.
133. Mackaness, G. B. 1956. The intracellular activation of pyrazinamide and nicotinamide. Am Rev Tubercul Pul Dis 74:718-28.
134. Sturgill-Koszycki, S., P. H. Schlesinger, P. Chakraborty, P. L. Haddix, H. L. Collins, A. K. Fok, R. D. Allen, S. L. Gluck, J. Heuser, and D. G. Russell. 1994. Lack of acidifi-cation in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263:678-81.
135. Scorpio, A., D. Collins, D. Whipple, D. Cave, J. Bates, and Y. Zhang. 1997. Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol 35:106-10.
136. Scorpio, A., L. P. Lindholm, L. Heifets, R. Gilman, S. Siddiqi, M. Cynamon, and Y. Zhang. 1997. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 41:540-3.
137. Scorpio, A., and Y. Zhang. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2:662-7.
138. Sreevatsan, S., X. Pan, Y. Zhang, B. N. Kreiswirth, and J. M. Musser. 1997. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 41:636-40.
139. Sun, Z., A. Scorpio, and Y. Zhang. 1997. The pncA gene from naturally pyrazinamideresistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms. Microbiology 143:3367-73.
140. Sun, Z., and Y. Zhang. 1999. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother 43:537-42.
141. Zhang, Y., A. Scorpio, H. Nikaido, and Z. Sun. 1999. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 181:2044-9.
142. Hirano, K., M. Takahashi, Y. Kazumi, Y. Fukasawa, and C. Abe. 1998. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tubercl Lung Dis 78:117-22.
143. Lemaitre, N., W. Sougakoff, C. Truffot-Pernot, and V. Jarlier. 1999. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother 43:1761-63.
144. Marttila, H. J., M. Marjamäki, E. Vyshnevskaya, B. I. Vyshnevskiy, T. F. Otten, A. V. Vasilyef, and M. K. Viljanen. 1999. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob Agents Chemother 43:1764-66.
145. Boshoff, H. I., and V. Mizrahi. 1998. Purification, gene cloning, targeted knockout, overexpression, and biochemical characterization of the major pyrazinamidase from Mycobacterium smegmatis. J Bacteriol 180:5809-14.
146. Raynaud, C., M.-A. Lanéelle, R. H. Senaratne, P. Draper, G. Lanéelle, and M. Daffé. 1999. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 145:1359-67.
147. Konno, K., F. M. Feldman, and W. McDermott. 1967. Pyrazinamide susceptibility and and amidase activity of tubercle bacilli. Am Rev Respir Dis 95:461-9.
148. McLaren, J., D. T. C. Ngo, and M. Olivera. 1973. Pyridine nucleotide metabolism in Escherichia coli. J Biol Chem 248:5144-9.
149. Takayama, K., and J. O. Kilburn. 1989. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 33:1493-9.
150. Khoo, K. H., E. Douglas, P. Azadi, J. M. Inamine, G. S. Besra, K. Mikusova, P. J. Brennan, and D. Chatterjee. 1996. Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis. Inhibition of arabinan biosynthesis by ethambutol. J Bacteriol Chem 271:28682-90.
151. Telenti, A., W. J. Philipp, S. Sreevatsan, C. Bernasconi, K. E. Stockbauer, B. Wieles, J. M. Musser, and W. J. Jacobs. 1997. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 3:567-70.
152. Belanger, A. E., G. S. Besra, M. E. Ford, K. Mikusova, J. T. Belisle, P. J. Brennan, and J. M. Inamine. 1996. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 93:11919-24.
153. Sharma, K., M. Gupta, M. Pathak, N. Gupta, A. Koul, S. Sarangi, R. Baweja, and Y. Singh. 2006. Transcriptional control of the mycobacterial embCAB operon by PknH through a regulatory protein, EmbR, in vivo. J Bacteriol 188:2936-44.
154. Lety, M. A., S. Nair, P. Berche, and V. Escuyer. 1997. A single point mutation in the embB gene is responsible for resistance to ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 41:2629-33.
155. Plinke, C., S. Rusch-Gerdes, and S. Niemann. 2006. Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 50:1900-2.
156. Sreevatsan, S., K. E. Stockbauer, X. Pan, B. N. Kreiswirth, S. L. Moghazeh, W. J. Jacobs, A. Telenti, and J. M. Musser. 1997. Ethambutol resistance in Mycobacterium tuberculosis : critical role of embB mutations. Antimicrob Agents Chemother 41:1677-81.
157. Alcaide, F., G. E. Pfyffer, and A. Telenti. 1997. Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrob Agents Chemother 41:2270-3.
158. Tsukamura, M. 1985. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280). Am Rev Respir Dis 131:348-51.
159. Tsukamura, M., E. Nakamura, S. Yoshii, and H. Amano. 1985. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 131:352-6.
160. Iseman, M. D. 1999. Management of multidrug-resistant tuberculosis. Chemotherapy 2:3-11.
161. Iseman, M. D. 1993. Treatment of multidrug-resistant tuberculosis. N Engl J Med 329:784-91.
162. Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O’Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169:421-6.
163. Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R. J. O’Brien, A. A. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacincontaining regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170:1131-4.
164. Camus, J. C., M. J. Pryor, C. Medigue, and S. T. Cole. 2002. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 148:2967-73.
165. Wang, J. C. 1985. DNA topoisomerases. Ann Rev Biochem 54:665-97.
166. Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistancedetermining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 34:1271-2.
167. Alangaden, G. J., E. K. Manavathu, S. B. Vakulenko, N. M. Zvonok, and S. A. Lerner. 1995. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 39:1700-3.
168. Cambau, E., W. Sougakoff, M. Besson, P. C. Truffot, J. Grosset, and V. Jarlier. 1994. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 170:479-83.
169. Takiff, H. E., L. Salazar, C. Guerrero, W. Philipp, W. M. Huang, B. Kreiswirth, S. T. Cole, W. J. Jacobs, and A. Telenti. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38:773-80.
170. Xu, C., B. N. Kreiswirth, S. Sreevatsan, J. M. Musser, and K. Drlica. 1996. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis 174:1127-30.
171. Aubry, A., N. Veziris, E. Cambau, C. Truffot-Pernot, V. Jarlier, and L. M. Fisher. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis : functional analysis of mutant enzymes. Antimicrob Agents Chemother 50:104-12.
172. Matrat, S., N. Veziris, C. Mayer, V. Jarlier, C. Truffot-Pernot, J. Camuset, E. Bouvet, E. Cambau, and A. Aubry. 2006. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother 50:4170-3.
173. Pitaksajjakul, P., W. Wongwit, W. Punprasit, B. Eampokalap, S. Peacock, and P. Ramasoota. 2005. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health 36 Suppl 4:228-37.
174. Sullivan, E. A., B. N. Kreiswirth, L. Palumbo, V. Kapur, J. M. Musser, A. Ebrahimzadeh, and T. R. Frieden. 1995. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 345:1148-50.
175. De Rossi, E., P. Arrigo, M. Bellinzoni, P. A. Silva, C. Martin, J. A. Ainsa, P. Guglierame, and G. Riccardi. 2002. The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol Med 8:714-24.
176. Pasca, M. R., P. Guglierame, F. Arcesi, M. Bellinzoni, E. De Rossi, and G. Riccardi. 2004. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother 48:3175-8.
177. Takiff, H. E., M. Cimino, M. C. Musso, T. Weisbrod, M. B. Delgado, L. Salazar, B. R. Bloom, and J. Jacobs, W.R. 1996. Efflux pump of the proton aniporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 93:362-366.
178. Buroni, S., G. Manina, P. Guglierame, M. R. Pasca, G. Riccardi, and E. De Rossi. 2006. LfrR is a repressor that regulates expression of the efflux pump LfrA in Mycobacterium smegmatis. Antimicrob Agents Chemother 50:4044-52.
179. Sander, P., E. De Rossi, B. Boddinghaus, R. Cantoni, M. Branzoni, E. C. Bottger, H. Takiff, R. Rodriquez, G. Lopez, and G. Riccardi. 2000. Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance. FEMS Microbiol Lett 193:19-23.
180. Montero, C., G. Mateu, R. Rodriguez, and H. Takiff. 2001. Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA. Antimicrob Agents Chemother 45:3387-92.
181. Vetting, M. W., S. S. Hegde, J. E. Fajardo, A. Fiser, S. L. Roderick, H. E. Takiff, and J. S. Blanchard. 2006. Pentapeptide repeat proteins. Biochemistry 45:1-10.
182. Hegde, S. S., M. W. Vetting, S. L. Roderick, L. A. Mitchenall, A. Maxwell, H. E. Takiff, and J. S. Blanchard. 2005. A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 308:1480-3.
183. Andries, K., P. Verhasselt, J. Guillemont, H. W. Gohlmann, J. M. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-7.
184. Ibrahim, M., K. Andries, N. Lounis, A. Chauffour, C. Truffot-Pernot, V. Jarlier, and N. Veziris. 2007. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 51:1011-5.
185. Lounis, N., N. Veziris, A. Chauffour, C. Truffot-Pernot, K. Andries, and V. Jarlier. 2006. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 50:3543-7.
186. Petrella, S., E. Cambau, A. Chauffour, K. Andries, V. Jarlier, and W. Sougakoff. 2006. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 50:2853-6.
187. Matsumoto, M., H. Hashizume, T. Tomishige, M. Kawasaki, H. Tsubouchi, H. Sasaki, Y. Shimokawa, and M. Komatsu. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466.
188. Stover, C. K., P. Warrener, D. R. VanDevanter, D. R. Sherman, T. M. Arain, M. H. Langhorne, S. W. Anderson, J. A. Towell, Y. Yuan, D. N. McMurray, B. N. Kreiswirth, C. E. Barry, and W. R. Baker. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962-6.
189. Choi, K. P., T. B. Bair, Y. M. Bae, and L. Daniels. 2001. Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG. J Bacteriol 183:7058-66.
190. Choi, K. P., N. Kendrick, and L. Daniels. 2002. Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J Bacteriol 184:2420-8.
191. Manjunatha, U. H., H. Boshoff, C. S. Dowd, L. Zhang, T. J. Albert, J. E. Norton, L. Daniels, T. Dick, S. S. Pang, and C. E. Barry, 3rd. 2006. Identification of a nitroimidazooxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 103:431-6.
192. Cole, S. T. 2002. Comparative and functional genomics of the Mycobacterium tuberculosis complex. Microbiology 148:2919-28.
193. Baker, L., T. Brown, M. C. Maiden, and F. Drobniewski. 2004. Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg Infect Dis 10:1568-77.
194. Hirsh, A. E., A. G. Tsolaki, K. DeRiemer, M. W. Feldman, and P. M. Small. 2004. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc Natl Acad Sci USA 101:4871-6.
195. Liu, X., M. M. Gutacker, J. M. Musser, and Y. X. Fu. 2006. Evidence for recombination in Mycobacterium tuberculosis. J Bacteriol 188:8169-77.